Cost-utility and cost-benefit analysis: How did we get here and where are we going?

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 6, 2004, Pages 527-534

  Moayyedi, Paul ^a   Mason, James ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Cost utility analysis; Quality adjusted life year; Willingness to pay

Indexed keywords

COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DYSPEPSIA; EVALUATION; GASTROENTEROLOGY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; IRRITABLE COLON; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

COST ALLOCATION; COST-BENEFIT ANALYSIS; GASTROENTEROLOGY; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH SERVICES RESEARCH; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 2542635628     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200406000-00004     Document Type: Review

References (46)

1. Mishan EJ. Welfare Economics. Ten Introductory Essays. New York: Random House; 1964.
2. Arrow KJ. Social Choice and Individual Values. Cowles Foundation Monograph 12, 2nd edn. New Haven, CT: Yale University Press; 1963.
3. Mullahy J. Live long, live well: quantifying the health of heterogeneous populations. Health Economics 2001; 10:429-440.
4. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1172-1177.
5. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37:53-72.
6. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002; 12:160-178.
7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339-1341.
8. De Wit GA, Busschbach JJ, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Economics 2000; 9:109-126.
9. Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Economics 1997; 16:155-175.
10. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337-343.
11. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316:736-741.
12. Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2:169-180.
13. Moayyedi P, Duffet S, Soo S, Axon ATR. The appropriateness of measuring the benefit of dyspepsia management in terms of quality adjusted life years [Abstract]. Gastroenterology 2001; 120:A239.
14. Martin AJ, Glasziou PP, Simes RJ, Lumley T. A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int J Tech Assess in Health Care 2000; 16:137-147.
15. Lundell L, Miettinen P, Myrvold HE, Pedereen SA, Thor K, Lamm M, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000; 12:879-887.
16. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993; 306:570-572.
17. Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, Allison JE. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001; 96:338-347.
18. Smith RD, Hall J, Gurney H, Harnett PR. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Med J Australia 1993; 158:319-322.
19. Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112:1078-1086.
20. Drummond M, O'Brien B, Stoddart, Torrance G. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press; 1997.
21. Arguedas MR, Heudebert GH, Stinnett AA, Wilcox CM. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. Am J Gastroenterol 2002; 97:898-904.
22. Ofman JJ, Dorn GH, Fennerty MB, Pass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16:261-273.
23. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407.
24. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol 1997; 8:65-70.
25. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997; 8: 1081-1087.
26. Stal JM, Gregor JC, Preiksaitis HG, Reynolds RP. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. Can J Gastroenterol 1998; 12:43-49.
27. Kievit J, van de Velde JH. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. Cancer 1990; 65: 2580-2587.
28. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
29. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost-effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum 2000; 43:1695-1703.
30. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001; 120:1640-1656.
31. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37:33-40.
32. Robinson R. Cost-benefit analysis. BMJ 1993; 307:924-926.
33. Mooney GH. Cost-benefit analysis and medical ethics. J Med Ethics 1980; 6:177-179.
34. Mintel International Group Limited. Gastro-intestinal Remedies. November 2002. http://reports.mintel.com
35. Ryan M. Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilization. Soc Sci Med 1999; 48:535-546.
36. Moayyedi P, Wardman M, Toner J, Ryan M, Duffett S. Establishing patient preferences for gastroenterology clinic reorganization using conjoint analysis. Eur J Gastroenterol Hepatol 2002; 14:429-433.
37. Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health 1982; 72:555-566.
38. Donaldson C. Eliciting patients' values by use of 'willingness to pay': letting the theory drive the method. Health Expectations 2001; 4: 180-188.
39. Kartman B. Utility and willingness to pay measurements among patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96 (8 suppl):S38-S43.
40. Moayyedi P, Duffett S, Axon ATR. How much are dyspeptic patients willing to pay for endoscopy compared with H. pylori 'test and treat'. Gut 2000; 46 (suppl II):A18.
41. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR 3rd, De Lissovoy G. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Int Med 2002; 162:1361-1366.
42. Cave M, Burningham D, Buxton M, Hanney S, Pollitt C, Scanlan M, Shurmer M. The Valuation of Changes in Quality in the Public Services. London: HMSO; 1993.
43. Busse R. Health care systems: towards an agenda for policy learning between Britain and Germany. Anglo-German Foundation: June 2002; available on http://www.agf.org.uk/pdfs/1363Healthweb.pdf
44. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308.
45. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000; 32:659-664.
46. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies. Med Decis Making 2000; 20:451-467.